Spotlight On... Yisheng Biopharma says Phase I rabies vaccine results positive; India considers drug trade margin cap; Astellas touts efficiency; Eisai completes acquisition; and more...

China's Yisheng Biopharma said it produced "positive topline results" from a Phase I clinical trial of its investigational PIKA rabies vaccine. The vaccine is designed to accelerate the immune response against postexposure rabies virus, the company said in a release. The company said the project to develop the vaccine, which uses a double-stranded RNA analog, was named a "National Key Medicine Innovation" in 2013 by China's National Ministry of Science and Technology. Rabies, which kills 60,000 people annually around the world, is a severe problem around the world in developing countries such as India and China. The disease's mortality rate is nearly 100% after the onset of clinical symptoms, the company said in its statement, adding that "fast production of neutralizing antibody … post vaccination is critical for life saving against the post-exposure rabies infection." The clinical trial was carried out at Singapore's SingHealth Investigational Medicine Unit. Release

> The government of India is considering capping margins on drug prices to lower the maximum retail price pharmacies and drug companies can charge in an effort to help the poor. Report

> India's SMS Pharmaceuticals won approval from the U.S. Food and Drug Administration for its API plant in Andhra Pradesh. Report

> Japan's Astellas Pharma says while it is smaller than its global rivals, its efficiency enables it to outperform in several areas. Report

> India's Vivimed Labs said it has received approval from competition authorities to sell products from its specialty chemicals division to Clariant Chemicals India for about $60 million. Report

> Sun Pharmaceutical Industries said it raised about $156 million selling nonconvertible debentures. Report

> Chinese researchers at the Institute of Modern Physics said they have developed a domestically made heavy-ion accelerator to be used in radiotherapy treatments. Report

> Indian telemedicine startup Doctor Insta said it has raised $500,000 from an angel investor and plans to raise upward of $2 million in additional funding to expand its business. Report

> Japan's Eisai said it has completed its acquisition of Liaoning Biological Pharmaceutical. Report

> The government of India said it may cap prices for drug-eluting coronary stents at about $423. Report

> India's patent office dealt a blow to AbbVie ($ABBV) when it rejected the company's multiple-variable dose regimen for a tumor necrosis factor alpha drug. Report

> India's Lupin received approval from the U.S. Food and Drug Administration for its generic version of Warner Chilcott's postmenopausal osteoporosis treatment Femhrt. Report

> Glenmark Pharmaceuticals said its generic version of Pfizer's ($PFE) antibacterial Zyvox has received approval from the U.S. Food and Drug Administration. Report

> Brazil has become the third country to approve Sanofi's ($SNY) Dengvaxia drug to combat dengue fever. Report

> A parliamentary panel in India has severely criticized the government for what it says are lapses in ensuring the quality and safety of ayurvedic and homeopathic medicines. Report

> North Carolina-based Clintrax Global said it was opening an office in Mumbai, India, to add to its global presence in clinical research. Release

Suggested Articles

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.